Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced December 20, 2024, as the date for its highly anticipated 2024 Annual Meeting of Stockholders. Find out all the details in this exclusive report!
Key Highlights:
- Shareholders on record as of October 25, 2024, will be eligible to vote at the meeting
- Deadline for proposal submissions is October 7, 2024
- New stock offerings registered to raise up to $1,146,894
- Phase 1/2 clinical trial of seclidemstat for Ewing sarcoma discontinued
- 1-for-8 reverse stock split announced to meet Nasdaq's bid price requirement
InvestingPro Insights:
According to InvestingPro data, SLRX's market capitalization is $2.09 million, with the stock trading near its 52-week low. The company holds more cash than debt but has not been profitable recently. SLRX's stock price has experienced high volatility, with recent total returns in the negative territory.
Investors should consider these key metrics before making any decisions regarding SLRX. Stay informed with InvestingPro's 15 additional tips for a more comprehensive analysis of this pharmaceutical stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
For more exclusive financial news and updates, click here!